Table 3.
5 | Survival after MVR | Survival after 1 Organ Resected |
Survival after >1 Organs Resected |
||||||
---|---|---|---|---|---|---|---|---|---|
1-Year | 3-Year | 5-Year | 1-Year | 3-Year | 5-Year | 1-Year | Year | 5-Year | |
Carboni et al. [4] | NM | NM | 21.8% | NM | NM | NM | NM | NM | NM |
Cheng et al. [15] | 55.2% | 22.4% | 12.2% | NM | NM | NM | NM | NM | NM |
Dias et al. [26] | NM | NM | 53.4% | NM | NM | NM | NM | NM | NM |
Isozaki et al. [16] | NM | NM | 35% | NM | NM | 40% | NM | NM | 10% |
Jeong et al. [17] | 74.0% | 56.5% | 47.5% | NM | NM | NM | NM | NM | NM |
Kim et al. [18] | NM | NM | 37.8% | NM | NM | NM | NM | NM | NM |
Kobayasbi et al. [27] | 59.8% | 40.9% | 31.1% | NM | NM | NM | NM | NM | NM |
Korenaga et al. [32] | NM | NM | NM | 78.2% | 54.2% | 39.5% | 42.9% | 21.4% | 21.4% |
Min et al. [19] | NM | NM | 37% | NM | NM | NM | NM | NM | NM |
Mita et al. [22] | NM | NM | NM | 82.5% | 47.4% | NM | 65.4% | 38.1% | NM |
Pacelli et al. [8] | 60.7% | 30.3% | 27.2% | NM | NM | 32.5% | NM | NM | 17.2% |
Molina et al. [9] | 88% | 51% | 34% | NM | NM | NM | NM | NM | NM |
Shchepotin et al. [29] | NM | NM | 25% | NM | NM | NM | NM | NM | NM |
Wang et al. [20] | 75% | 49.2% | 36.9% | NM | NM | NM | NM | NM | NM |
Yang et al. [21] | 56.1% | 26.2% | 15.4% | 59.3% | 26.9% | 17.3% | 50% | 18.1% | 6.9% |
Ozer et al. [12] | 53.3% | 36% | 28.1% | 62.3% | 40.8% | NM | 30.0% | 6.4% | NM |
Sahakyan et al. [11] | NM | 18% | 10.8% | NM | NM | NM | NM | NM | NM |
Total: | 65.2% (62.61–67.8%) |
33.05% (30.71–35.5%) |
30.21% (28.25–32.25%) |
64.46% (60.39–68.37%), |
42.33% (38.19–46.43%), |
32.33% (28.95–35.9%) |
47.1% (40.58–53.63%) |
21% (15.96–26.67%) |
15.17% (11.3–20%) |